FDA Again Delays Nod For Novo Nordisk Long-Acting Insulin
The U.S. Food and Drug Administration has delayed for the second time a decision on whether to approve Danish pharmaceutical company Novo Nordisk A/S's potential blockbuster diabetes treatment insulin degludec pending review...To view the full article, register now.
Already a subscriber? Click here to view full article